EMA Authorised: Ogivri (trastuzumab) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

The EMA authorised Ogivri, a trastuzumab biosimilar from Biosimilar Collaborations Ireland Limited, for gastric cancer and breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• OGIVRI (trastuzumab-dkst)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms;Breast Neoplasms. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 20/02/2026